Effector Therapeutics Inc (EFTR) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access EFTR Annual Balance Sheets →
The data below summarizes Effector Therapeutics Inc's balance sheet position from Mar 31 2023 to Mar 31 2024, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2024)
(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Assets
Cash & cash equivalent15.51
Short-term Investments, Total9.88
Cash & Short-term Investments24.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.87
Total Current Assets26.25
Equipment/Property/Plant Net0.19
Other Assets, Noncurrent0.69
Operating Lease Right Of Use Asset0.23
Total Assets27.13
Liabilities
Accounts Payable, Current AC1.71
Accrued Liabilities, Current AC3.79
Other Liabilities, Current20.07
Total Current Liabilities25.57
Total Long-term Debt0.00
Other liabilities, Noncurrent0.74
OperatingLeaseLiabilityNoncurrent0.18
Term Loans Net18.92
Earn Out Liability-
Operating Lease Liability Current0.05
Total Liabilities26.30
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock189.04
Retained Earnings / Accumulated Deficit-188.21
Other Equity0.00
Common Stockholder's Equity0.83
Total Stockholder's Equity0.83
Liabilities & Stockholder's Equity27.13
4 historic quarters locked

Sign in to unlock the full Effector Therapeutics Inc balance sheet history.

About Effector Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-056859

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.